SCHEMBL3883349

SCHEMBL3883349

Cc1c(Cl)cccc1S(=O)(=O)CNCc1cccc(C(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 8/20 0.52
MEP1B Q16820 4/20 0.48
WDR5 P61964 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
MYC P01106 1/20 0.46
NR1H4 Q96RI1 1/20 0.44
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
MITF O75030 1/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
XBP1 P17861 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
KMT2A Q03164 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
FABP4 P15090 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3874145 0.84 FABP4 (0.56) MRGPRX4WDR5NR1H4TP53FABP4
SCHEMBL3874658 0.81 ROCK2 (0.47) CA1CA2MEN1NPC1HPGD
SCHEMBL3883351 0.76 MRGPRX4 (0.52) MRGPRX4MEP1BWDR5MEN1NPC1
SCHEMBL3879413 0.76 PFKFB3 (0.63) MRGPRX4
SCHEMBL3877794 0.74 CA1 (0.55) MRGPRX4MEP1BCA1CA2
SCHEMBL3873274 0.73 FABP4 (0.49) MRGPRX4TP53FABP4
SCHEMBL30444148 0.72 MEP1B (0.65) MRGPRX4MEP1BCA1CA2MYC
SCHEMBL16366609 0.72 MEP1B (0.65) MRGPRX4MEP1BCA1CA2MYC
SCHEMBL13894125 0.71 MRGPRX4 (0.52) MRGPRX4MEP1BNR1H4MEN1HPGD
SCHEMBL3876675 0.70 HSD11B1 (0.53) NPC1TP53HPGDRAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed
EP-1814846-A1 11BETA-HSD1 INHIBITORS Evotec AG (DE) 2007-08-08 EP disclosed
WO-2006048330-A1 11ΒΕΤΑ-HSD1 INHIBITORS EVOTEC AG (DE) 2006-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 MRGPRX4 1361/4885MEP1B 1091/4885WDR5 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.